Since different methylation profiles may act as potential biomarkers of modifiable disease pathways, the methylation profiles of selected CpG’s sites spanning regulatory regions of the IL4, IL5, IL10, IFNG and FOXP3 genes from infants with FA, AD and with symptoms of both (ADFA), as well as healthy subjects were investigated. This evidence concerns the gene IL10 and Alzheimer disease.